Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan 30;8(1):9.
doi: 10.1186/s13550-018-0364-x.

It is time to move forward into the era of Theranostics

Hojjat Ahmadzadehfar  1 , Markus Essler  2
Affiliations

It is time to move forward into the era of Theranostics

Hojjat Ahmadzadehfar et al. EJNMMI Res. .

Abstract

Radionuclide therapy, which until 15 years ago included only a few approved therapies, is gaining importance in the treatment of various malignancies. The future of oncology will not be limited to surgery, chemo-, antibody therapies or external radiation; it will include targeted therapy with radionuclides, which will become the standard of care for a variety of malignant diseases in combination or as an alternative to other therapies. Therefore there is a need to train Nuclear Oncologists, who are able to approach oncological diseases, promote development of radiopharmacy, understand the biology of radionuclide treatment, apply radionuclide treatments and be able to use molecular imaging such as PET/CT and SPECT/CT for treatment planning and dosimetry.

Keywords: Fellowship; Oncology; Radionuclide therapy; Theranostics.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Competing interests

Both authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Similar articles

See all similar articles

Cited by

References

    1. Braat AJ, Smits ML, Braat MN, van den Hoven AF, Prince JF, de Jong HW, et al. (9)(0)Y hepatic radioembolization: an update on current practice and recent developments. J Nucl Med. 2015;56:1079–1087. doi: 10.2967/jnumed.115.157446. - DOI - PubMed
    1. Yordanova A, Mayer K, Brossart P, Gonzalez-Carmona MA, Strassburg CP, Essler M, et al. Safety of multiple repeated cycles of 177Lu-octreotate in patients with recurrent neuroendocrine tumour. Eur J Nucl Med Mol Imaging. 2017;44:1207–1214. doi: 10.1007/s00259-017-3652-1. - DOI - PubMed
    1. Bodei L, Cremonesi M, Grana CM, Chinol M, Baio SM, Severi S, et al. Yttrium-labelled peptides for therapy of NET. Eur J Nucl Med Mol Imaging. 2012;39(Suppl 1):S93–102. doi: 10.1007/s00259-011-2002-y. - DOI - PubMed
    1. Tennvall J, Fischer M, Bischof Delaloye A, Bombardieri E, Bodei L, Giammarile F, et al. EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin) Eur J Nucl Med Mol Imaging. 2007;34:616–622. doi: 10.1007/s00259-007-0372-y. - DOI - PubMed
    1. Liepe K, Kotzerke J. Internal radiotherapy of painful bone metastases. Methods. 2011;55:258–270. doi: 10.1016/j.ymeth.2011.07.001. - DOI - PubMed

LinkOut - more resources